November 20, 2025, Baltimore, MD – SilcsBio, a technology company that develops and markets software and services for structure-based drug design, is excited to announce the hiring of Steven Gossert, Ph.D. as Applications Scientist, Computational Drug Design.
Over the last several years, Steven has worked as a postdoctoral modeling scientist in Drug Product Development at Bristol-Myers Squibb. At BMS, Steven worked on developing modeling workflows to predict
key formulation properties for both biologics and small molecules. In these efforts, Steven employed SILCSBio in the biologics formulation pipeline to enable faster formulation development. He also spearheaded efforts to use modeling tools to speed up formulation development and adopt a model-first approach for drugdevelopment decreasing development times and helping more drug products to market. In his previous role, Steven worked on several innovative uses for the SILCS Biologics suite to solve problems in biologics formulations and he hopes to continue those efforts in his new role increasing the use cases and applicability for SILCSBio in pharmaceutical development.
Steven earned his Bachelor of Chemical Engineering from Rowan University in Glassboro, NJ. His undergraduate work focused on thermoplastic membranes, green thermoset polymer chemistry and mechanical properties of hydrogels. He then received his PhD in Chemical and Biological Engineering from Drexel University with a focus on understanding mechanisms of novel anti-HIV drugs using molecular simulations and free energy methods.
About SilcsBio:
SilcsBio, LLC offers the SILCS platform technology that advances computational drug design applications through detailed protein mapping that accounts for flexibility and solvation and enables highly efficient ligand binding evaluation, virtual screening, and more. SilcsBio software and services span from target protein mapping and analysis through lead optimization and offers key insights for biological therapeutic formulations. The proprietary software unlocks hidden binding hotspots of target proteins and reveals the preferred ligand chemistries at those sites to rapidly guide the drug design process. SilcsBio most recently announced a partnership with Aikido Pharmaceuticals. Learn more: www.silcsbio.com
